The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 14, 2023. Its latest SEC filing is a SC 13G/A from Feb 8, 2024.
10-Q for Q2 FY2023, filed Aug 14, 2023
The sections below describe the company as of the FY2022 annual report.
Develops a cannabidiol skin gel for behavioral symptoms of Fragile X syndrome and a chromosome deletion syndrome.
10-K for FY2022, filed Mar 28, 2023We are currently developing Zygel (also known as ZYN002), the first and only pharmaceutically-produced cannabidiol formulated as a…View ↗
Zygel is being developed as a clear gel and is targeting treatment of behavioral symptoms of FXS and 22q. We have received orphan drug…View ↗
Our clinical programs for Zygel include ongoing and planned clinical trials evaluating Zygel in the treatment of behavioral symptoms of FXS…View ↗
10-Q for Q2 FY2023, filed Aug 14, 2023
−$10.8MView ↗
8-K, filed Oct 11, 2023
On October 10, 2023, Harmony Biosciences Holdings, Inc., a Delaware corporation (“Parent”) completed the previously announced acquisition…View ↗
Narrower target conditions
The older report listed autism and developmental and epileptic encephalopathies among Zygel’s target conditions, while the latest report describes development for Fragile X and the chromosome deletion syndrome.
10-K for FY2019, filed Mar 10, 2020 10-K for FY2022, filed Mar 28, 2023Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare…View ↗
We are currently evaluating ZygelTM, a patent-protected transdermal cannabidiol, or CBD, gel for the treatment of FXS, DEE, ASD and 22q. In…View ↗
Zygel is the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery, and the…View ↗
Competes with Tetra Therapeutics, Allos Pharma, and Nobias Therapeutics
10-K for FY2022, filed Mar 28, 2023There are no drugs approved for the treatment of FXS or its most common symptoms, although various classes of medications are used…View ↗
Loading...
